OTLK Outlook Therapeutics

Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event

Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast presentation on Tuesday, January 17th at 11:00 AM ET

ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that of Outlook Therapeutics will present at the on Tuesday, January 17, 2023 at 11:00 AM ET.

A of the presentation will be available on the page of the section of Outlook Therapeutics’ website . A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.



About Outlook Therapeutics, Inc.



Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit .

CONTACTS:

Media Inquiries:

Anna Army

Account Supervisor

LaVoie Health Science

T: 617-351-0246

Investor Inquiries:       

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 



EN
09/01/2023

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Ea...

March 25, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.2...

March 24, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics Announces Proposed Public Offering ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its common stock (or pre-funded warrants in lieu thereof) and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to th...

March 23, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note ...

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the “Existing Note”) and the issuance of a new non-convertible, unsecured note with Atlas Sciences, LLC (the “New Note”). Under the amendment to the Existing Note, the maturity date of the Ex...

March 16, 2026 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg). The Type A meeting was c...

March 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch